Evidence map›Paper›PMID 32872376›Full record

ArticleNutrients2020

Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats.

Juste Maneikyte, Augustinas Bausys, Bettina Leber, Nicole Feldbacher, Gerald Hoefler, Dagmar Kolb-Lenz, Kestutis Strupas, Philipp Stiegler, Peter Schemmer

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Peripheral vascular remodeling during ischemia.Frontiers in pharmacology · 2022
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Juste ManeikyteGeneral, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.
Augustinas BausysGeneral, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.
Bettina LeberGeneral, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-2101-7560
Nicole FeldbacherGeneral, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.
Gerald HoeflerDiagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Dagmar Kolb-LenzInstitute of Cell Biology, Histology and Embryology, Medical University Graz, 8010 Graz, Austria.
Kestutis StrupasFaculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.
Philipp StieglerGeneral, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.
Peter SchemmerGeneral, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.
Medical University of Graz · ATVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFOLFOX chemotherapy (CTx) is used for the treatment of colorectal liver metastasis (CRLM). Side effects include rare cardiotoxicity, which may limit the application of FOLFOX. Currently, there is no effective strategy to prevent FOLFOX-induced cardiotoxicity. Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion. This study tested the hypothesis of glycine being cardioprotective in a rat model of FOLFOX in combination with CRLM. MATERIALS AND

methodsThe effect of glycine was tested in vitro on human cardiac myocytes (HCMs). To test glycine in vivo Wag/Rij rats with induced CRLM were treated with FOLFOX ±5% dietary glycine. Left ventricle ejection fraction (LVEF), myocardial fibrosis, and apoptosis, also heart fatty acid binding protein (h-FABP) and brain natriuretic peptide levels were monitored. PCR analysis for Collagen type I, II, and brain natriuretic peptide (BNP) in the heart muscle was performed.

resultsIn vitro glycine had no effect on HCM cell viability. Treatment with FOLFOX resulted in a significant increase of h-FABP levels, increased myocardial fibrosis, and apoptosis as well as increased expression of type I Collagen. Furthermore, FOLFOX caused a decrease of LVEF by 10% (

conclusionsData presented here demonstrate for the first time that dietary glycine protects the heart against FOLFOX-induced injury during treatment for CRLM.

Indexed as

AnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDietDisease Models, AnimalFluorouracilGlycineHeart InjuriesLeucovorinLiver NeoplasmsMaleOrganoplatinum CompoundsRatsAntineoplastic AgentsFluorouracilGlycineLeucovorinOrganoplatinum Compoundscardiotoxicitycolorectal cancerFOLFOXglycine

Identifiers

PMID32872376
PMCPMC7551625
OpenAlexW3082181874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.